GLP-1 receptor agonists have become increasingly common treatments for obesity, type 2 diabetes, and metabolic disorders. While these medications have demonstrated significant benefits for weight management and glucose regulation, relatively little research has examined their effects on female hormonal health and reproductive physiology.

This study aims to investigate the relationship between GLP-1 medications and changes in female hormone profiles across different stages of life. Researchers will evaluate hormonal biomarkers, menstrual cycle characteristics, reproductive health measures, metabolic indicators, and patient-reported outcomes to better understand how these medications may influence endocrine function. The study will also explore whether factors such as age, body composition, pre-existing hormonal conditions, and treatment duration are associated with differences in physiological responses.

The long-term goal of this research is to generate high-quality evidence that can help healthcare providers better understand the interactions between GLP-1 therapies and women's hormonal health, ultimately supporting more informed clinical decision-making and identifying priorities for future research.